GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer

Summary

This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT201 injection ) in combination with teraplizumab injection for treatment of patients with non-small cell lung cancer,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).

Timeline

Start

2024-02-02

Primary completion

2025-12-30

Completion

2025-12-30

Outcome

Outcome not reported

Stopped (Business): “The study was terminated from a business perspective.”

Drugs

Indications